
pmid: 36727226
pmc: PMC12770703
In July of 2020, bulevirtide was conditionally approved for the treatment of adults with compensated chronic hepatitis D. Some clinical studies have evaluated the safety and efficacy of bulevirtide as a treatment option for chronic hepatitis D in recent years. Herein are presented a brief review and an outline.
Adult, Lipopeptides, Hepatitis D, Chronic, Humans, Antiviral Agents
Adult, Lipopeptides, Hepatitis D, Chronic, Humans, Antiviral Agents
| citations The total number of citations received by all articles of the researcher of interest. | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
